MyFinsight
Home
Blog
About
Filspari
$13,567K
Kyprolis
$7,044K
Royalty Intangible
Other
$4,269K
Intangible Ohtuvayre
$4,144K
Rylaze
$3,201K
Capvaxive
$2,316K
Teriparatide Injection
$1,470K
Vaxneuvance
$1,351K
QARZIBA
$6,150K
Financial Ohtuvayre
Inventors
$3,294K
Financial Royalty Other
$1,226K
Intangible Royalty Assets
$37,362K
Financial Royalty Assets
$10,670K
Contract And Revenue
Income Other
$5,000K
Contract Revenue
$2,683K
Royalty
$48,032K
Material Sales Captisol
$7,978K
Contract Revenue And
Other Income
$7,683K
Loss (gain) from
change in fair value of...
$35,727K
Loss (gain) from
short-term investments
$11,754K
Interest income
$7,298K
Other non-operating
expense, net
$2,682K
Total revenues and
income
$63,693K
Total non-operating
income (expenses), net
$55,713K
Operating income (gain)
$8,591K
Interest expense
$1,748K
Total operating costs
and expenses
$55,102K
Income (gain) before
income taxes
$64,304K
General and
administrative
$29,123K
Research and development
$14,668K
Amortization of intangibles
$8,097K
Cost of captisol
$3,214K
Net income (gain)
$48,508K
Income tax (expense)
benefit
$15,796K
Back
Back
Income Statement
LIGAND PHARMACEUTICALS INC (LGNYZ)
LIGAND PHARMACEUTICALS INC (LGNYZ)
source: myfinsight.com